Serum interleukin-1 beta plays an important role in insulin secretion in type II diabetic

Paper Details

Research Paper 01/06/2011
Views (330) Download (5)
current_issue_feature_image
publication_file

Serum interleukin-1 beta plays an important role in insulin secretion in type II diabetic

Eizadi Mojtaba, Kohandel Mahdi, kasbparast JR Mehdi, Sarshin Amir
Int. J. Biosci.1( 3), 93-99, June 2011.
Certificate: IJB 2011 [Generate Certificate]

Abstract

The proinflammatory cytokine Interleukin-1beta is increased in presence obesity or its related disorders. The objective of this study was to determine serum IL-1β in relation to some markers indicative of type II diabetic. For this purpose, blood samples were collected from brachial vein after a overnight fast between 8:00 and 9:00 a.m. o’clock in order to measuring serum IL-1β, glucose, insulin and beta cell function in a group of type II diabetic men patients (n = 30) and none-diabetic healthy subjects (n = 36) matched for BMI and age in order 1) to compare serum IL-1b between diabetic and none-diabetic subjects, 2) to determine serum IL-1b in relation to fasting glucose, insulin and beta-cell function in diabetic patients. All anthropometrical indexes were also measured in two groups. Statistical analysis was performed by Independent sample T-test and Spearman rank correlation method. P value of <0.05 was accepted as significant. Insulin resistance and fasting glucose and serum IL-1b were significantly higher and serum insulin and Beta cell function were significantly lower in diabetic patients than none-diabetic subjects (p < 0.05). Serum IL-1b was negatively correlated with insulin and beta cell function and positively related with fasting glucose in diabetic patients (p < 0.05). Based on this data, it was concluded that IL-1b as a inflammation cytokine play a important role in type II diabetic and insulin secretion of pancreatic beta cell.

VIEWS 8

Andersson AK, Flodstr¨om M, Sandler S. 2001. Cytokineinduced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase,” Biochemicaland Biophysical Research Communications 281(2), 396–403.

Azevedo-Martins AK, Lortz S, Lenzen S, Curi R, Eizirik DL, Tiedge M. 2003. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-κB activation in insulin-producing cells,” Diabetes 52(1), 93–101.

Bendtzen K, Mandrup-Poulsen T, Nerup J. 1986. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 232, 1545 -7.

Dinarello CA. 2009. Immunological and infl ammatory functions of the interleukin-1 family. Annu Rev Immunol 27, 519 -50.

Ehses JA, Lacraz G, Giroix MH, Schmidlin F, Coulaud J, Kassis N. 2009. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 106(33), 13998-4003.

Ehses JA, Lacraz G, Giroix MH. 2009. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat,” Proceedings of the National Academy of Sciences of the United States of America 106(33), 13998– 14003.

 

Eizirik DL. 1988. Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor. Acta Endocrinol (Copenh) 119, 321 -5.

Greenman Y, Golani N, Gilad S, Yaron M, Limor R, Stern N. 2004. Ghrelin secretion is modulated in a nutrient- and gender-specific manner. Clin Endocrinol (Oxf) 60(3), 382-8.

Juge-Aubry CE,  Somm  E,  Giusti  V. 2003. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and infl ammation. Diabetes 52, 1104 -10.

Kahn SE. 2003. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46, 3–19.

Kawasaki E, Abiru N, Eguchi K. 2004. Prevention of type 1 diabetes: from the view point of β cell damage,” Diabetes Research and Clinical Practice 66(supplement 1), 27–32.

Kiely A, McClenaghan NH, Flatt PR, Newsholme P. 2007. Pro-inflammatory cytokines increase glucose, alanine and triacylglycerol utilization but inhibit insulin secretion in a clonal pancreatic β-cell line. The Journal of Endocrinology 195(1), 113–123.

Kim DJ, Lee MS, Kim KW, Lee MK. 2011. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism 50, 590–593.

Maedler K, Dharmadhikari G, Schumann DM, Størling J. 2009. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert Opin Biol Ther 9(9),1177-88.

Maedler K, Schumann DM, Sauter N. 2006. Low concentration of interleukin-1 β Induces FLICE- inhibitory protein-mediated β -cell proliferation in human pancreatic islets. Diabetes 55, 2713 -22.

Mandrup-Poulsen    T, Bendtzen K, Nerup J. 1998. Affi nity-purifi ed human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 29, 63 -7.

Manica-Cattani MF, Bittencourt L, Rocha MI, Algarve TD, Bodanese LC, Rech R. 2010. Association between interleukin-1 beta polymorphism (+3953) and obesity. Mol Cell Endocrinol 314(1), 84-9.

Matsuki T, Horai R, Sudo K, Iwakura Y. 2003. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med 198(6), 877-88.

Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S. 1997. Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 20, 1562–1568.

Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T. 2008. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine 44(1), 141-8.

Retnakaran R, Hanley AJ, Raif N, Hirning CR, Connelly PW, Sermer M. 2005. Adiponectin and beta cell dysfunction in gestational diabetes: pathophysiological implications. Diabetologia 48(5), 993-1001.

Sauter  NS, Schulthess FT, Galasso R. 2008. The antiinfl amatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology 149, 2208 – 18.

Schumann DM, Maedler K, Franklin I. 2007. The Fas pathway is involved in β -cell secretory function. Proc Natl Acad Sci USA 104, 2861 -6.

Suk K, Kim S, Kim YH. 2001. IFN-γ/TNF-α synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic/β cell death. Journal of Immunology 166(7), 4481–4489.

Vincent JA, Mohr S. 2007. Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56(1), 224-30.

Wang C, Guan Y, Yang J. 2010. Cytokines in the Progression of Pancreatic β-Cell Dysfunction. Int J Endocrinol 5, 15136.

Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. 2010. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells,” Nutrition Reviews 68(5), 270–279.

Zhang S, Kim KH. 1995. TNF-α inhibits glucose-induced insulin secretion in a pancreatic β-cell line (INS-1). FEBS Letters 377(2), 237–239.